Key result
Doxorubicin induces cardiotoxicity via premature cardiac senescence, offering a potential target for cardioprotection.
Why the study?
Doxorubicin clinical use is limited by dose-dependent cardiotoxicity associated with premature cardiac senescence, requiring an understanding of mechanisms to develop effective cardioprotective strategies.
Design
Review
Authors
Loading...
DOX cardiotoxicity involves premature cardiac senescence; leaves open whether senescence-targeted therapies alter clinical outcomes.
This review highlights the role of premature cardiac senescence in doxorubicin-induced cardiotoxicity and discusses potential therapeutic strategies to mitigate heart failure risk in cancer patients.
Bai et al. (2026) conducted a review in Doxorubicin-induced cardiotoxicity and cardiac senescence. Doxorubicin was evaluated. Doxorubicin-induced cardiotoxicity is driven by premature cardiac senescence across multiple cell populations, disrupting cardiac homeostasis and contributing to pathological remodeling.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: